A Phase II Open-Label Study Of Recombinant Human Interleukin-12 (NSC 672423) In Mycosis Fungoides (MF) Patients With Cross-Over To Phase I Evaluation Of Escalating Doses Of Interleukin-2 (NSC 373364) Administered With Interleukin-12
Phase of Trial: Phase I/II
Latest Information Update: 15 Jan 2013
At a glance
- Drugs Interleukin-12 (Primary) ; Interleukin-2
- Indications Cancer; Mycosis fungoides
- Focus Adverse reactions; Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 15 Jan 2013 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 06 Oct 2005 New trial record.